Published in Nat Med on October 07, 2013
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) (2014) 2.10
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature (2016) 1.63
REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature (2015) 1.50
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PLoS One (2016) 1.47
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. J Clin Invest (2016) 1.43
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol (2015) 1.41
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer (2016) 1.41
BRCAness revisited. Nat Rev Cancer (2016) 1.38
PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med (2015) 1.16
DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer (2015) 1.10
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
New perspectives on targeted therapy in ovarian cancer. Int J Womens Health (2015) 0.98
The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene (2014) 0.98
Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res (2014) 0.96
Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy. J Ovarian Res (2013) 0.95
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest (2016) 0.94
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. Mol Cell (2015) 0.91
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res (2015) 0.91
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res (2016) 0.87
TIRR regulates 53BP1 by masking its histone methyl-lysine binding function. Nature (2017) 0.87
Readers of poly(ADP-ribose): designed to be fit for purpose. Nucleic Acids Res (2015) 0.87
Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. Cancer Res (2014) 0.86
Precision medicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol (2015) 0.85
Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future. Cancers (Basel) (2014) 0.84
Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Comput Biol (2015) 0.83
Autoimmune response to PARP and BRCA1/BRCA2 in cancer. Oncotarget (2015) 0.83
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol (2014) 0.83
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. Am J Nucl Med Mol Imaging (2016) 0.83
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget (2016) 0.82
FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. Cell Rep (2016) 0.82
Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience (2016) 0.81
New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract (2016) 0.80
Alternative splicing of DNA damage response genes and gastrointestinal cancers. World J Gastroenterol (2014) 0.80
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One (2014) 0.80
Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics (2014) 0.79
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines. J Breast Cancer (2015) 0.78
Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. ACS Chem Biol (2015) 0.78
Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines. Cell Rep (2014) 0.78
Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell Death Dis (2014) 0.78
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun (2016) 0.78
Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol (2016) 0.77
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib. Sci Rep (2015) 0.77
Salivary α-amylase, serum albumin, and myoglobin protect against DNA-damaging activities of ingested dietary agents in vitro. Food Chem Toxicol (2014) 0.77
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist (2016) 0.77
Cell cycle-dependent inhibition of 53BP1 signaling by BRCA1. Cell Discov (2015) 0.77
Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Mol Syst Biol (2015) 0.77
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer. J Pathol (2017) 0.77
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol (2017) 0.76
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. BMC Cancer (2015) 0.76
Peptides with in vitro anti-tumor activity from the venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae). J Venom Res (2014) 0.76
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res (2016) 0.76
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci Rep (2016) 0.76
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget (2017) 0.76
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst (2016) 0.76
THE GORDON WILSON LECTURE EVOLUTION OF CLINICAL CANCER GENETICS. Trans Am Clin Climatol Assoc (2016) 0.75
Hypermutation signature reveals a slippage and realignment model of translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. Proc Natl Acad Sci U S A (2017) 0.75
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev (2017) 0.75
Targeting DNA Replication Stress for Cancer Therapy. Genes (Basel) (2016) 0.75
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance. Elife (2017) 0.75
Drugging the Cancers Addicted to DNA Repair. J Natl Cancer Inst (2017) 0.75
Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract (2016) 0.75
Impaired 53BP1/RIF1 DSB mediated end-protection stimulates CtIP-dependent end resection and switches the repair to PARP1-dependent end joining in G1. Oncotarget (2016) 0.75
Reverse the Resistance to PARP Inhibitors. Int J Biol Sci (2017) 0.75
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget (2016) 0.75
Distinguishing between cancer cell differentiation and resistance induced by all-trans retinoic acid using transcriptional profiles and functional pathway analysis. Sci Rep (2014) 0.75
Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol (2016) 0.75
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells. J Cancer Prev (2014) 0.75
A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. Case Rep Oncol (2016) 0.75
Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther (2016) 0.75
The Impact of DNA Repair Pathways in Cancer Biology and Therapy. Cancers (Basel) (2017) 0.75
Systems analysis of dynamic transcription factor activity identifies targets for treatment in olaparib resistant cancer cells. Biotechnol Bioeng (2017) 0.75
Role of RAD51AP1 in homologous recombination DNA repair and carcinogenesis. DNA Repair (Amst) (2017) 0.75
Thwarting endogenous stress: BRCA protects against aldehyde toxicity. EMBO Mol Med (2017) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Clonal evolution in cancer. Nature (2012) 11.07
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
The DNA damage response and cancer therapy. Nature (2012) 5.25
Role of poly(ADP-ribose) formation in DNA repair. Nature (1992) 4.98
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
The emerging landscape of breast cancer susceptibility. Nat Genet (2008) 4.27
53BP1 regulates DSB repair using Rif1 to control 5' end resection. Science (2013) 4.00
Integrating genetic approaches into the discovery of anticancer drugs. Science (1997) 3.99
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell (2013) 3.55
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell (2012) 3.10
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell (2013) 3.05
Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. Science (2013) 3.02
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 2.35
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell (2012) 2.21
Evolutionary plasticity of genetic interaction networks. Nat Genet (2008) 1.97
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics (1946) 1.83
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res (2010) 1.64
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res (2012) 1.61
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle (2012) 1.50
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem (2011) 1.29
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res (2009) 1.26
Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res (2003) 1.23
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol (2013) 1.20
ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des (2014) 1.15
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One (2013) 1.11
RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. Cancer Res (2012) 1.02
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov (2011) 1.01
53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes. Gynecol Oncol (2012) 0.83
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Arch (2012) 0.79
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
The DNA damage response and cancer therapy. Nature (2012) 5.25
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Stem cells and breast cancer: A field in transit. Nat Rev Cancer (2003) 3.47
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Functional and molecular characterisation of mammary side population cells. Breast Cancer Res (2002) 2.63
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov (2012) 2.53
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 2.43
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell (2008) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta (2004) 2.04
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med (2002) 1.97
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol (2010) 1.94
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
MAP kinase phosphatases. Genome Biol (2002) 1.88
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J (2003) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study. Am J Epidemiol (2014) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet (2007) 1.74
Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet (2004) 1.73
DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev (2008) 1.73
Pregnancy and the risk of breast cancer. Endocr Relat Cancer (2007) 1.72
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) (2008) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J (2009) 1.68
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause (2011) 1.63
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov (2012) 1.62
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol (2011) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell (2010) 1.52
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep (2004) 1.52
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
A genome-wide association study of early menopause and the combined impact of identified variants. Hum Mol Genet (2013) 1.50
Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep (2009) 1.50
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med (2009) 1.49
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res (2013) 1.47
Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol (2010) 1.47
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med (2014) 1.47
LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology (2010) 1.47
Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 1.47
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst (2011) 1.45
Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1. Oncogene (2003) 1.43
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A (2011) 1.42
Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol (2005) 1.40
Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol (2007) 1.40
Signalling pathways implicated in early mammary gland morphogenesis and breast cancer. PLoS Genet (2006) 1.40
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. Am J Hum Genet (2013) 1.39
A novel short splice variant of the tumour suppressor LKB1 is required for spermiogenesis. Biochem J (2008) 1.38
Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab Invest (2007) 1.35
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest (2008) 1.35
Searching for synthetic lethality in cancer. Curr Opin Genet Dev (2011) 1.34
p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep (2006) 1.34
Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One (2009) 1.33
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat (2006) 1.32